The 27th Congress of the European Hematology Association (EHA) 2022, held in Vienna, Austria, and virtually, from 9 - 12 June 2022, saw leading experts from around the world gather to discuss the most exciting updates in the field of hematology. Key updates on CAR-T therapy, transplant research, novel drugs, and more were showcased across the spectrum of hematological diseases, including CLL, AML, multiple myeloma, lymphomas, CML, ALL, sickle cell disease, thalassemia, and beyond.  
View all videos

EHA 2022

EHA 2022
09–12 June 2022 | Vienna Austria / Online
Retweet on TwitterVJHemOnc Retweeted
ESmithMDPhDEric Smith@ESmithMDPhD·
11h

Our report of first-in-human GPRC5D-targeted CAR T cells for MM is out in NEJM! The trial was led by Sham Mailankody and could not be done without the amazing clinical, correlative science, stats, & cell manufacturing teams.
Happy to share our bench>bedside journey
1/10

Reply on Twitter 1575279224923082752Retweet on Twitter 157527922492308275291Like on Twitter 1575279224923082752399View Tweet 1575279224923082752
Retweet on TwitterVJHemOnc Retweeted
adamssperlingAdam Sperling, MD, PhD@adamssperling·
12h

Very excited to see this incredible work led by Sham Mailankody and @ESmithMDPhD published in @NEJM. An incredible bench-to-bedside story leading to real progress for our patients. Looking forward to seeing what comes next. https://www.nejm.org/doi/full/10.1056/NEJMoa2209900

Reply on Twitter 1575267136854839297Retweet on Twitter 15752671368548392978Like on Twitter 157526713685483929737View Tweet 1575267136854839297
VJHemOncVJHemOnc@VJHemOnc·
32m

It’s the second day of #SOHO22 & we’re so happy to be here in-person, speaking with several experts at the forefront of hematology.👨‍⚕️👩‍⚕️

Stay tuned for our exclusive interviews!🎥

@SocietyofHemOnc #MMsm #LeuSM #AMLsm #ALLsm #LymSM #MDSsm #MPNsm #CLLsm #ImmunoOnc #HemOnc

Reply on Twitter 1575440609648705537Retweet on Twitter 15754406096487055371Like on Twitter 15754406096487055371View Tweet 1575440609648705537
VJHemOncVJHemOnc@VJHemOnc·
2h

📣Join us for another weekly podcast!

Tune in as experts Amer Zeidan, Rena Buckstein, and Valeria Santini discuss key updates from iwMDS 2022!

Listen here:

🎧: http://ow.ly/YIf050KWGwR

#HemOnc #MDSsm #BloodCancerAwarenessMonth

Reply on Twitter 1575422570438041601Retweet on Twitter 15754225704380416011Like on Twitter 1575422570438041601View Tweet 1575422570438041601
Load More...

EHA 2022

EHA 2022
09–12 June 2022 | Vienna Austria / Online
The 27th Congress of the European Hematology Association (EHA) 2022, held in Vienna, Austria, and virtually, from 9 - 12 June 2022, saw leading experts from around the world gather to discuss the most exciting updates in the field of hematology. Key updates on CAR-T therapy, transplant research, novel drugs, and more were showcased across the spectrum of hematological diseases, including CLL, AML, multiple myeloma, lymphomas, CML, ALL, sickle cell disease, thalassemia, and beyond.  
View all videos
Retweet on TwitterVJHemOnc Retweeted
ESmithMDPhDEric Smith@ESmithMDPhD·
11h

Our report of first-in-human GPRC5D-targeted CAR T cells for MM is out in NEJM! The trial was led by Sham Mailankody and could not be done without the amazing clinical, correlative science, stats, & cell manufacturing teams.
Happy to share our bench>bedside journey
1/10

Reply on Twitter 1575279224923082752Retweet on Twitter 157527922492308275291Like on Twitter 1575279224923082752399View Tweet 1575279224923082752
Retweet on TwitterVJHemOnc Retweeted
adamssperlingAdam Sperling, MD, PhD@adamssperling·
12h

Very excited to see this incredible work led by Sham Mailankody and @ESmithMDPhD published in @NEJM. An incredible bench-to-bedside story leading to real progress for our patients. Looking forward to seeing what comes next. https://www.nejm.org/doi/full/10.1056/NEJMoa2209900

Reply on Twitter 1575267136854839297Retweet on Twitter 15752671368548392978Like on Twitter 157526713685483929737View Tweet 1575267136854839297
VJHemOncVJHemOnc@VJHemOnc·
32m

It’s the second day of #SOHO22 & we’re so happy to be here in-person, speaking with several experts at the forefront of hematology.👨‍⚕️👩‍⚕️

Stay tuned for our exclusive interviews!🎥

@SocietyofHemOnc #MMsm #LeuSM #AMLsm #ALLsm #LymSM #MDSsm #MPNsm #CLLsm #ImmunoOnc #HemOnc

Reply on Twitter 1575440609648705537Retweet on Twitter 15754406096487055371Like on Twitter 15754406096487055371View Tweet 1575440609648705537
VJHemOncVJHemOnc@VJHemOnc·
2h

📣Join us for another weekly podcast!

Tune in as experts Amer Zeidan, Rena Buckstein, and Valeria Santini discuss key updates from iwMDS 2022!

Listen here:

🎧: http://ow.ly/YIf050KWGwR

#HemOnc #MDSsm #BloodCancerAwarenessMonth

Reply on Twitter 1575422570438041601Retweet on Twitter 15754225704380416011Like on Twitter 1575422570438041601View Tweet 1575422570438041601
Load More...

Latest videos

View all videos
5:07
The impact of bariatric surgery on the outcomes of patients with CML treated with TKIs
Fadi Haddad • 24 Jun 2022
0:54
The importance of genomics-based stratification in multiple myeloma
Monique Minnema • 11 Jun 2022
1:20
A comparison of bispecific antibodies emerging in multiple myeloma
Monique Minnema • 11 Jun 2022
1:18
Updates from the MonumenTAL-1 trial
Monique Minnema • 11 Jun 2022

Press Briefings

View all
3:58
RBP dysregulation and its impact on bone marrow failure and hematopoietic stem cell biology
Pedro Aguilar-Garrido • 11 Jun 2022
7:39
CLIMB THAL-111 and CLIMB SCD-121: exa-cel gene therapy in TDT and SCD
Franco Locatelli • 11 Jun 2022
5:41
Primary results from the Phase III SHINE study: ibrutinib + BR for older patients with MCL
Michael Wang • 11 Jun 2022
5:00
Venetoclax-obinutuzumab is superior to chemoimmunotherapy in frontline CLL: updates from GAIA/CLL13
Barbara Eichhorst • 11 Jun 2022

Non-Hodgkin Lymphoma

View all
4:06
The impact of RBPs in the development of hematological malignancies and bone marrow failure
Miguel Gallardo • 23 Jun 2022
1:03
The importance of circulating tumor DNA in patients with primary CNS lymphoma
Won Seog Kim • 11 Jun 2022

Hodgkin Lymphoma

View all
2:41
ECHELON-1 trial updates: overall survival data
Graham Collins • 11 Jun 2022
1:44
Treatment options for transplant-ineligibile HL patients
Paul Jan Bröckelmann • 10 Jun 2022

Chronic lymphocytic leukemia

View all
1:10
The role of next-generation BTK inhibitors in the treatment of CLL
Matthew Davids • 12 Jun 2022
3:06
Updated PFS results of the GAIA/CLL13 trial
Barbara Eichhorst • 20 Jun 2022

Acute lymphoblastic leukemia

View all
5:14
Novel synthetic TCR and antigen receptor (STAR) T-cell therapy for B-ALL
Peihua Lu • 16 Jun 2022
2:34
Exploring chemotherapy-free induction treatment for patients with Ph+ ALL
Robin Foà • 11 Jun 2022

Acute myeloid leukemia

View all
4:06
The impact of RBPs in the development of hematological malignancies and bone marrow failure
Miguel Gallardo • 23 Jun 2022
3:47
The role of immunotherapy in the AML treatment landscape
Thomas Cluzeau • 12 Jun 2022

Multiple Myeloma

View all
0:54
The importance of genomics-based stratification in multiple myeloma
Monique Minnema • 11 Jun 2022
1:20
A comparison of bispecific antibodies emerging in multiple myeloma
Monique Minnema • 11 Jun 2022

MPNs

View all
3:03
An insight into the MOMENTUM trial: safety and efficacy of momelotinib for the treatment of MF
Srdan Verstovsek • 22 Jun 2022
1:48
The evolving role of AI in MPNs
Claire Harrison • 13 Jun 2022

Rare Diseases

View all
0:42
Approaching NK/T-cell lymphoma
Won Seog Kim • 11 Jun 2022
5:39
Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL
Peihua Lu • 16 Jun 2022
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals